IDH2 and oligodendroglioma: Oligodendrogliomas, IDH-mutant, 1p19q-codeleted have an average annual incidence of 0.48 per 100,000, and typically appear in patients between their fourth and fifth decade of life, with a median overall survival of 10–17 years depending on patient demographics, tumour size and location, and the pursued treatment protocol [1,42].